Optimer Fires Execs For Questionable Financial Practices
This article was originally published in The Pink Sheet Daily
Executive Summary
A year after FDA approval of its antibiotic Dificid, the Optimer board has ousted its chairman and at least two other top executives.
You may also be interested in...
Optimer's Early Sales Of Dificid Topping Analyst Projections
The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.
Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.
Optimer Pharmaceuticals Inc.
The company is developing an easy to use platform technology for the rapid assembly of single-chain, straight-branched oligosaccharides--a rational design appproach to carbohydrate drug discovery.